{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T09:06:23Z","timestamp":1779267983057,"version":"3.51.4"},"reference-count":84,"publisher":"Siapec Servizi Srl","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathologica"],"DOI":"10.32074\/1591-951x-1812","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T08:15:39Z","timestamp":1779264939000},"page":"96-107","source":"Crossref","is-referenced-by-count":0,"title":["Golden rules for optimizing the diagnostic pathway of IDH-mutant tumors: bridging evidence and clinical practice in cholangiocarcinoma and adult-type diffuse gliomas"],"prefix":"10.32074","volume":"118","author":[{"given":"Manila","family":"Antonelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Barresi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Bertero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Daniele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Fassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umberto","family":"Malapelle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Normanno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giancarlo","family":"Pruneri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aldo","family":"Scarpa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"21774","published-online":{"date-parts":[[2026,5]]},"reference":[{"key":"10.32074\/1591-951X-1812_ref1","doi-asserted-by":"crossref","unstructured":"Intern\u00f2 V, Melaccio A, Vitale P, et al. Therapeutic inhibition of isocitrate dehydrogenase mutations in glioma and cholangiocarcinoma: new insights and promises \u2013 a narrative review. Chinese Clinical Oncology. 2024;13(5):69","DOI":"10.21037\/cco-24-17"},{"key":"10.32074\/1591-951X-1812_ref2","doi-asserted-by":"crossref","unstructured":"Zhang X, Han J, Shi R, et al. Guideline of precisional testing in intrahepatic cholangiocarcinoma: an international expert consensus. Clinical Cancer Bulletin. 2025;4(1):9. https:\/\/doi.org\/10.1007\/s44272-025-00036-0","DOI":"10.1007\/s44272-025-00036-0"},{"key":"10.32074\/1591-951X-1812_ref3","doi-asserted-by":"crossref","unstructured":"Normanno N, Martinelli E, Melisi D, et al. Role of molecular genetics in the clinical management of cholangiocarcinoma. ESMO Open. 2022;7(3):100505. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100505","DOI":"10.1016\/j.esmoop.2022.100505"},{"key":"10.32074\/1591-951X-1812_ref4","doi-asserted-by":"crossref","unstructured":"Fassan M, Angerilli V, Normanno N, et al. Practical guidelines for molecular testing of cholangiocarcinoma in clinical practice: Italian experts\u2019 position paper. Crit Rev Oncol Hematol. 2024;194:104224. https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104224","DOI":"10.1016\/j.critrevonc.2023.104224"},{"key":"10.32074\/1591-951X-1812_ref5","doi-asserted-by":"crossref","unstructured":"Cohen AL, Holmen SL, Colman H. IDH1 and IDH2 mutations in gliomas. Curr Neurol Neurosci Rep. 2013;13(5):345. https:\/\/doi.org\/10.1007\/s11910-013-0345-4","DOI":"10.1007\/s11910-013-0345-4"},{"key":"10.32074\/1591-951X-1812_ref6","doi-asserted-by":"crossref","unstructured":"Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell.. 2010;18(6):553-67. https:\/\/doi.org\/10.1016\/j.ccr.2010.11.015","DOI":"10.1016\/j.ccr.2010.11.015"},{"key":"10.32074\/1591-951X-1812_ref7","doi-asserted-by":"crossref","unstructured":"Xu W, Yang H, Liu Y, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell.. 2011;19(1):17-30. https:\/\/doi.org\/10.1016\/j.ccr.2010.12.014","DOI":"10.1016\/j.ccr.2010.12.014"},{"key":"10.32074\/1591-951X-1812_ref8","doi-asserted-by":"crossref","unstructured":"Wang F, Travins J, DeLaBarre B, et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science. 2013;340(6132):622-6. https:\/\/doi.org\/10.1126\/science.1234769","DOI":"10.1126\/science.1234769"},{"key":"10.32074\/1591-951X-1812_ref9","doi-asserted-by":"crossref","unstructured":"Losman JA, Looper RE, Koivunen P, et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science. 2013;339(6127):1621-5. https:\/\/doi.org\/10.1126\/science.1231677","DOI":"10.1126\/science.1231677"},{"key":"10.32074\/1591-951X-1812_ref10","doi-asserted-by":"crossref","unstructured":"Kernytsky A, Wang F, Hansen E, et al. IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition. Blood. 2015;125(2):296-303. https:\/\/doi.org\/10.1182\/blood-2013-10-533604","DOI":"10.1182\/blood-2013-10-533604"},{"key":"10.32074\/1591-951X-1812_ref11","doi-asserted-by":"crossref","unstructured":"Abou-Alfa GK, Macarulla T, Javle MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(6):796-807. https:\/\/doi.org\/10.1016\/S1470-2045(20)30157-1","DOI":"10.1016\/S1470-2045(20)30157-1"},{"key":"10.32074\/1591-951X-1812_ref12","doi-asserted-by":"crossref","unstructured":"Goyal L, Govindan A, Sheth RA, et al. Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma. Oncologist. 2015;20(9):1019-27. https:\/\/doi.org\/10.1634\/theoncologist.2015-0210","DOI":"10.1634\/theoncologist.2015-0210"},{"key":"10.32074\/1591-951X-1812_ref13","doi-asserted-by":"crossref","unstructured":"Vogel A, Ducreux M, clinicalguidelines@esmo.org EGCEa. ESMO Clinical Practice Guideline interim update on the management of biliary tract cancer. ESMO Open. 2025;10(1):104003. https:\/\/doi.org\/10.1016\/j.esmoop.2024.104003","DOI":"10.1016\/j.esmoop.2024.104003"},{"key":"10.32074\/1591-951X-1812_ref14","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Biliary Tract Cancers, Version 2.2025. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1517 (accessed 15 July 2025). ["},{"key":"10.32074\/1591-951X-1812_ref15","doi-asserted-by":"crossref","unstructured":"Capper D, Sahm F, Hartmann C, et al. Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes. Am J Surg Pathol. 2010;34(8):1199-204. https:\/\/doi.org\/10.1097\/PAS.0b013e3181e7740d","DOI":"10.1097\/PAS.0b013e3181e7740d"},{"key":"10.32074\/1591-951X-1812_ref16","doi-asserted-by":"crossref","unstructured":"Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009;118(4):469-74. https:\/\/doi.org\/10.1007\/s00401-009-0561-9","DOI":"10.1007\/s00401-009-0561-9"},{"key":"10.32074\/1591-951X-1812_ref17","doi-asserted-by":"crossref","unstructured":"Reuss DE, Sahm F, Schrimpf D, et al. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an \u201cintegrated\u201d diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol. 2015;129(1):133-46. https:\/\/doi.org\/10.1007\/s00401-014-1370-3","DOI":"10.1007\/s00401-014-1370-3"},{"key":"10.32074\/1591-951X-1812_ref18","doi-asserted-by":"crossref","unstructured":"Mellinghoff IK, van den Bent MJ, Blumenthal DT, et al. Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma. N Engl J Med. 2023;389(7):589-601. https:\/\/doi.org\/10.1056\/NEJMoa2304194","DOI":"10.1056\/NEJMoa2304194"},{"key":"10.32074\/1591-951X-1812_ref19","doi-asserted-by":"crossref","unstructured":"Houillier C, Wang X, Kaloshi G, et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology. 2010;75(17):1560-6. https:\/\/doi.org\/10.1212\/WNL.0b013e3181f96282","DOI":"10.1212\/WNL.0b013e3181f96282"},{"key":"10.32074\/1591-951X-1812_ref20","doi-asserted-by":"crossref","unstructured":"Babakoohi S, Lapidus RG, Faramand R, et al. Comparative Analysis of Methods for Detecting Isocitrate Dehydrogenase 1 and 2 Mutations and Their Metabolic Consequence, 2-Hydroxyglutarate, in Different Neoplasms. Appl Immunohistochem Mol Morphol 2017;25(5):334-7. https:\/\/doi.org\/10.1097\/PAI.0000000000000342","DOI":"10.1097\/PAI.0000000000000342"},{"key":"10.32074\/1591-951X-1812_ref21","doi-asserted-by":"crossref","unstructured":"Mosele MF, Westphalen CB, Stenzinger A, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2024;35(7):588-606. https:\/\/doi.org\/10.1016\/j.annonc.2024.04.005","DOI":"10.1016\/j.annonc.2024.04.005"},{"key":"10.32074\/1591-951X-1812_ref22","doi-asserted-by":"crossref","unstructured":"Malone ER, Oliva M, Sabatini PJB, et al. Molecular profiling for precision cancer therapies. Genome Med. 2020;12(1):8. https:\/\/doi.org\/10.1186\/s13073-019-0703-1","DOI":"10.1186\/s13073-019-0703-1"},{"key":"10.32074\/1591-951X-1812_ref23","doi-asserted-by":"crossref","unstructured":"Hinrichs JW, van Blokland WT, Moons MJ, et al. Comparison of next-generation sequencing and mutation-specific platforms in clinical practice. Am J Clin Pathol. 2015;143(4):573-8. https:\/\/doi.org\/10.1309\/AJCP40XETVYAMJPY","DOI":"10.1309\/AJCP40XETVYAMJPY"},{"key":"10.32074\/1591-951X-1812_ref24","doi-asserted-by":"crossref","unstructured":"Moorcraft SY, Gonzalez D, Walker BA. Understanding next generation sequencing in oncology: A guide for oncologists. Crit Rev Oncol Hematol. 2015;96(3):463-74. https:\/\/doi.org\/10.1016\/j.critrevonc.2015.06.007","DOI":"10.1016\/j.critrevonc.2015.06.007"},{"key":"10.32074\/1591-951X-1812_ref25","doi-asserted-by":"crossref","unstructured":"DiPeri TP, Javle MM, Meric-Bernstam F. Next generation sequencing for biliary tract cancers. Expert Rev Gastroenterol Hepatol. 2021;15(5):471-4. https:\/\/doi.org\/10.1080\/17474124.2021.1896967","DOI":"10.1080\/17474124.2021.1896967"},{"key":"10.32074\/1591-951X-1812_ref26","doi-asserted-by":"crossref","unstructured":"Kendall T, Overi D, Guido M, et al. Recommendations on maximising the clinical value of tissue in the management of patients with intrahepatic cholangiocarcinoma. JHEP Rep. 2024;6(6):101067. https:\/\/doi.org\/10.1016\/j.jhepr.2024.101067","DOI":"10.1016\/j.jhepr.2024.101067"},{"key":"10.32074\/1591-951X-1812_ref27","doi-asserted-by":"crossref","unstructured":"Ma L, Guo H, Zhao Y, et al. Liquid biopsy in cancer: current status, challenges and future prospects. Signal Transduct Target Ther. 2024;9(1):336. https:\/\/doi.org\/10.1038\/s41392-024-02021-w","DOI":"10.1038\/s41392-024-02021-w"},{"key":"10.32074\/1591-951X-1812_ref28","doi-asserted-by":"crossref","unstructured":"Pope WB, Prins RM, Albert Thomas M, et al. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. J Neurooncol. 2012;107(1):197-205. https:\/\/doi.org\/10.1007\/s11060-011-0737-8","DOI":"10.1007\/s11060-011-0737-8"},{"key":"10.32074\/1591-951X-1812_ref29","doi-asserted-by":"crossref","unstructured":"Normanno N, Apostolidis K, Wolf A, et al. Access and quality of biomarker testing for precision oncology in Europe. Eur J Cancer. 2022;176:70-7. https:\/\/doi.org\/10.1016\/j.ejca.2022.09.005","DOI":"10.1016\/j.ejca.2022.09.005"},{"key":"10.32074\/1591-951X-1812_ref30","doi-asserted-by":"crossref","unstructured":"Weller M, van den Bent M, Preusser M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2021;18(3):170-86. https:\/\/doi.org\/10.1038\/s41571-020-00447-z","DOI":"10.1038\/s41571-020-00447-z"},{"key":"10.32074\/1591-951X-1812_ref31","doi-asserted-by":"crossref","unstructured":"Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803-20. https:\/\/doi.org\/10.1007\/s00401-016-1545-1","DOI":"10.1007\/s00401-016-1545-1"},{"key":"10.32074\/1591-951X-1812_ref32","doi-asserted-by":"crossref","unstructured":"Brat DJ, Aldape K, Colman H, et al. cIMPACT-NOW update 3: recommended diagnostic criteria for \u201cDiffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV\u201d. Acta Neuropathol. 2018;136(5):805-10. https:\/\/doi.org\/10.1007\/s00401-018-1913-0","DOI":"10.1007\/s00401-018-1913-0"},{"key":"10.32074\/1591-951X-1812_ref33","unstructured":"NCCN. (2023, March 24). NCCN Clinical Practice Guidelines in Oncology; Central Nervous System Cancers v1.2023. National Comprehensive Cancer Network. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cns.pdf ["},{"key":"10.32074\/1591-951X-1812_ref34","doi-asserted-by":"crossref","unstructured":"Nabors B, Portnow J, Hattangadi-Gluth J, et al. NCCN CNS tumor guidelines update for 2023. Neuro Oncol. 2023;25(12):2114-6. https:\/\/doi.org\/10.1093\/neuonc\/noad169","DOI":"10.1093\/neuonc\/noad169"},{"key":"10.32074\/1591-951X-1812_ref35","doi-asserted-by":"crossref","unstructured":"Horbinski C, Nabors LB, Portnow J, et al. NCCN Guidelines(R) Insights: Central Nervous System Cancers, Version 2.2022. J Natl Compr Canc Netw. 2023;21(1):12-20. https:\/\/doi.org\/10.6004\/jnccn.2023.0002","DOI":"10.6004\/jnccn.2023.0002"},{"key":"10.32074\/1591-951X-1812_ref36","doi-asserted-by":"crossref","unstructured":"Dutta R, Vallurupalli M, McVeigh Q, et al. Understanding inequities in precision oncology diagnostics. Nat Cancer. 2023;4(6):787-94. https:\/\/doi.org\/10.1038\/s43018-023-00568-1","DOI":"10.1038\/s43018-023-00568-1"},{"key":"10.32074\/1591-951X-1812_ref37","doi-asserted-by":"crossref","unstructured":"Uson Junior PLS, DeLeon TT, Bogenberger JM, et al. FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations. Dig Dis Sci. 2022;67(8):3797-805. https:\/\/doi.org\/10.1007\/s10620-021-07303-9","DOI":"10.1007\/s10620-021-07303-9"},{"key":"10.32074\/1591-951X-1812_ref38","doi-asserted-by":"crossref","unstructured":"Rizzato M, Brignola S, Munari G, et al. Prognostic impact of FGFR2\/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study. Eur J Cancer. 2022;166:165-75. https:\/\/doi.org\/10.1016\/j.ejca.2022.02.013","DOI":"10.1016\/j.ejca.2022.02.013"},{"key":"10.32074\/1591-951X-1812_ref39","doi-asserted-by":"crossref","unstructured":"Koehne de Gonzalez A, Mansukhani MM, Fernandes H, et al. Pan-tumor screening for NTRK gene fusions using pan-TRK immunohistochemistry and RNA NGS fusion panel testing. Canc Genet. 2022;262-263:47-52. https:\/\/doi.org\/10.1016\/j.cancergen.2021.12.010","DOI":"10.1016\/j.cancergen.2021.12.010"},{"key":"10.32074\/1591-951X-1812_ref40","doi-asserted-by":"crossref","unstructured":"Kikuchi AT, Umetsu S, Joseph N, et al. Genomic Analysis in the Categorization of Poorly Differentiated Primary Liver Carcinomas. Am J Surg Pathol. 2023;47(11):1207-18. https:\/\/doi.org\/10.1097\/PAS.0000000000002116","DOI":"10.1097\/PAS.0000000000002116"},{"key":"10.32074\/1591-951X-1812_ref41","doi-asserted-by":"crossref","unstructured":"Cao Z, Yang Y, Liu S, et al. FGFR2 fusions assessed by NGS, FISH, and immunohistochemistry in intrahepatic cholangiocarcinoma. J Gastroenterol. 2025;60(2):235-46. https:\/\/doi.org\/10.1007\/s00535-024-02175-y","DOI":"10.1007\/s00535-024-02175-y"},{"key":"10.32074\/1591-951X-1812_ref42","doi-asserted-by":"crossref","unstructured":"Lapin M, Huang HJ, Chagani S, et al. Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With IDH-Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase Inhibitors. JCO Precis Oncol. 2022;6:e2100197. https:\/\/doi.org\/10.1200\/PO.21.00197","DOI":"10.1200\/PO.21.00197"},{"key":"10.32074\/1591-951X-1812_ref43","doi-asserted-by":"crossref","unstructured":"Kamath SD, Lin X, Kalyan A. A Case of Metastatic Biliary Tract Cancer Diagnosed Through Identification of an IDH1 Mutation. Oncologist. 2019;24(2):151-6. https:\/\/doi.org\/10.1634\/theoncologist.2018-0210","DOI":"10.1634\/theoncologist.2018-0210"},{"key":"10.32074\/1591-951X-1812_ref44","doi-asserted-by":"crossref","unstructured":"Driescher C, Fuchs K, Haeberle L, et al. Bile-Based Cell-Free DNA Analysis Is a Reliable Diagnostic Tool in Pancreatobiliary Cancer. Cancers (Basel). 2020;13(1). https:\/\/doi.org\/10.3390\/cancers13010039","DOI":"10.3390\/cancers13010039"},{"key":"10.32074\/1591-951X-1812_ref45","doi-asserted-by":"crossref","unstructured":"Demols A, Rocq L, Perez-Casanova L, et al. A Two-Step Diagnostic Approach for NTRK Gene Fusion Detection in Biliary Tract and Pancreatic Adenocarcinomas. Oncologist. 2023;28(7):e520-e5. https:\/\/doi.org\/10.1093\/oncolo\/oyad075","DOI":"10.1093\/oncolo\/oyad075"},{"key":"10.32074\/1591-951X-1812_ref46","doi-asserted-by":"crossref","unstructured":"Peraldo-Neia C, Scatolini M, Grosso E, et al. Assessment of a High Sensitivity Method for Identification of IDH1 R132x Mutations in Tumors and Plasma of Intrahepatic Cholangiocarcinoma Patients. Cancers (Basel). 2019;11(4). https:\/\/doi.org\/10.3390\/cancers11040454","DOI":"10.3390\/cancers11040454"},{"key":"10.32074\/1591-951X-1812_ref47","doi-asserted-by":"crossref","unstructured":"Lamarca A, Kapacee Z, Breeze M, et al. Molecular Profiling in Daily Clinical Practice: Practicalities in Advanced Cholangiocarcinoma and Other Biliary Tract Cancers. J Clin Med. 2020;9(9). https:\/\/doi.org\/10.3390\/jcm9092854","DOI":"10.3390\/jcm9092854"},{"key":"10.32074\/1591-951X-1812_ref48","unstructured":"Hwang S, Woo S, Kang B, et al. Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer. J Hepatol. 2025;82(4):649-57. https:\/\/doi.org\/10.1016\/j.jhep.2024. https:\/\/doi.org\/10.020"},{"key":"10.32074\/1591-951X-1812_ref49","doi-asserted-by":"crossref","unstructured":"Csoma SL, Bedekovics J, Veres G, et al. Circulating Cell-Free DNA-Based Comprehensive Molecular Analysis of Biliary Tract Cancers Using Next-Generation Sequencing. Cancers (Basel). 2022;14(1). https:\/\/doi.org\/10.3390\/cancers14010233","DOI":"10.3390\/cancers14010233"},{"key":"10.32074\/1591-951X-1812_ref50","doi-asserted-by":"crossref","unstructured":"Berchuck JE, Facchinetti F, DiToro DF, et al. The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer. Ann Oncol. 2022;33(12):1269-83. https:\/\/doi.org\/10.1016\/j.annonc.2022.09.150","DOI":"10.1016\/j.annonc.2022.09.150"},{"key":"10.32074\/1591-951X-1812_ref51","doi-asserted-by":"crossref","unstructured":"Astier C, Ngo C, Colmet-Daage L, et al. Molecular profiling of biliary tract cancers reveals distinct genomic landscapes between circulating and tissue tumor DNA. Exp Hematol Oncol. 2024;13(1):2. https:\/\/doi.org\/10.1186\/s40164-023-00470-7","DOI":"10.1186\/s40164-023-00470-7"},{"key":"10.32074\/1591-951X-1812_ref52","doi-asserted-by":"crossref","unstructured":"Bhamidipati D, Verma A, Sui D, et al. An analysis of research biopsy core variability from over 5000 prospectively collected core samples. NPJ Precis Oncol. 2021;5(1):94. https:\/\/doi.org\/10.1038\/s41698-021-00234-8","DOI":"10.1038\/s41698-021-00234-8"},{"key":"10.32074\/1591-951X-1812_ref53","doi-asserted-by":"crossref","unstructured":"Mahmood U, Muhamad Faizul E, Howlett S, et al. Comprehensive Examination of Cholangiocarcinoma Patients Treated with Novel Targeted Therapies after Extended Molecular Profiling on Liquid Biopsies. Cancers (Basel). 2024;16(4). https:\/\/doi.org\/10.3390\/cancers16040697","DOI":"10.3390\/cancers16040697"},{"key":"10.32074\/1591-951X-1812_ref54","doi-asserted-by":"crossref","unstructured":"Tomczak A, Springfeld C, Dill MT, et al. Precision oncology for intrahepatic cholangiocarcinoma in clinical practice. Br J Cancer. 2022;127(9):1701-8. https:\/\/doi.org\/10.1038\/s41416-022-01932-1","DOI":"10.1038\/s41416-022-01932-1"},{"key":"10.32074\/1591-951X-1812_ref55","doi-asserted-by":"crossref","unstructured":"Sledzinska P, Bebyn M, Szczerba E, et al. Glioma 2021 WHO Classification: The Superiority of NGS Over IHC in Routine Diagnostics. Mol Diagn Ther. 2022;26(6):699-713. https:\/\/doi.org\/10.1007\/s40291-022-00612-3","DOI":"10.1007\/s40291-022-00612-3"},{"key":"10.32074\/1591-951X-1812_ref56","doi-asserted-by":"crossref","unstructured":"Jabbar KJ, Luthra R, Patel KP, et al. Comparison of next-generation sequencing mutation profiling with BRAF and IDH1 mutation-specific immunohistochemistry. Am J Surg Pathol. 2015;39(4):454-61. https:\/\/doi.org\/10.1097\/PAS.0000000000000325","DOI":"10.1097\/PAS.0000000000000325"},{"key":"10.32074\/1591-951X-1812_ref57","doi-asserted-by":"crossref","unstructured":"Wu Z, Abdullaev Z, Pratt D, et al. Impact of the methylation classifier and ancillary methods on CNS tumor diagnostics. Neuro Oncol. 2022;24(4):571-81. https:\/\/doi.org\/10.1093\/neuonc\/noab227","DOI":"10.1093\/neuonc\/noab227"},{"key":"10.32074\/1591-951X-1812_ref58","doi-asserted-by":"crossref","unstructured":"White CL, Kinross KM, Moore MK, et al. Implementation of DNA Methylation Array Profiling in Pediatric Central Nervous System Tumors: The AIM BRAIN Project: An Australian and New Zealand Children\u2019s Haematology\/Oncology Group Study. J Mol Diagn. 2023;25(10):709-28. https:\/\/doi.org\/10.1016\/j.jmoldx.2023.06.013","DOI":"10.1016\/j.jmoldx.2023.06.013"},{"key":"10.32074\/1591-951X-1812_ref59","doi-asserted-by":"crossref","unstructured":"Pickles JC, Fairchild AR, Stone TJ, et al. DNA methylation-based profiling for paediatric CNS tumour diagnosis and treatment: a population-based study. Lancet Child Adolesc Health. 2020;4(2):121-30. https:\/\/doi.org\/10.1016\/S2352-4642(19)30342-6","DOI":"10.1016\/S2352-4642(19)30342-6"},{"key":"10.32074\/1591-951X-1812_ref60","doi-asserted-by":"crossref","unstructured":"Jaunmuktane Z, Capper D, Jones DTW, et al. Methylation array profiling of adult brain tumours: diagnostic outcomes in a large, single centre. Acta Neuropathol Commun. 2019;7(1):24. https:\/\/doi.org\/10.1186\/s40478-019-0668-8","DOI":"10.1186\/s40478-019-0668-8"},{"key":"10.32074\/1591-951X-1812_ref61","doi-asserted-by":"crossref","unstructured":"Capper D, Jones DTW, Sill M, et al. DNA methylation-based classification of central nervous system tumours. Nature. 2018;555(7697):469-74. https:\/\/doi.org\/10.1038\/nature26000","DOI":"10.1038\/nature26000"},{"key":"10.32074\/1591-951X-1812_ref62","doi-asserted-by":"crossref","unstructured":"Binder H, Willscher E, Loeffler-Wirth H, et al. DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II\/III gliomas resolve cancer heterogeneity and development. Acta Neuropathol Commun. 2019;7(1):59. https:\/\/doi.org\/10.1186\/s40478-019-0704-8","DOI":"10.1186\/s40478-019-0704-8"},{"key":"10.32074\/1591-951X-1812_ref63","doi-asserted-by":"crossref","unstructured":"Lam LHT, Do DT, Diep DTN, et al. Molecular subtype classification of low-grade gliomas using magnetic resonance imaging-based radiomics and machine learning. NMR Biomed. 2022;35(11):e4792. https:\/\/doi.org\/10.1002\/nbm.4792","DOI":"10.1002\/nbm.4792"},{"key":"10.32074\/1591-951X-1812_ref64","doi-asserted-by":"crossref","unstructured":"Nam YK, Park JE, Park SY, et al. Reproducible imaging-based prediction of molecular subtype and risk stratification of gliomas across different experience levels using a structured reporting system. Eur Radiol. 2021;31(10):7374-85. https:\/\/doi.org\/10.1007\/s00330-021-08015-4","DOI":"10.1007\/s00330-021-08015-4"},{"key":"10.32074\/1591-951X-1812_ref65","doi-asserted-by":"crossref","unstructured":"Li M, Ren X, Chen X, et al. Combining hyperintense FLAIR rim and radiological features in identifying IDH mutant 1p\/19q non-codeleted lower-grade glioma. Eur Radiol. 2022;32(6):3869-79. https:\/\/doi.org\/10.1007\/s00330-021-08500-w","DOI":"10.1007\/s00330-021-08500-w"},{"key":"10.32074\/1591-951X-1812_ref66","doi-asserted-by":"crossref","unstructured":"Luo H, Zhuang Q, Wang Y, et al. A novel image signature-based radiomics method to achieve precise diagnosis and prognostic stratification of gliomas. Lab Invest. 2021;101(4):450-62. https:\/\/doi.org\/10.1038\/s41374-020-0472-x","DOI":"10.1038\/s41374-020-0472-x"},{"key":"10.32074\/1591-951X-1812_ref67","doi-asserted-by":"crossref","unstructured":"Goyal A, Yolcu YU, Goyal A, et al. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p\/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance. Neurosurg Focus. 2019;47(6):E13. https:\/\/doi.org\/10.3171\/2019.9.FOCUS19660","DOI":"10.3171\/2019.9.FOCUS19660"},{"key":"10.32074\/1591-951X-1812_ref68","doi-asserted-by":"crossref","unstructured":"Fukuma R, Yanagisawa T, Kinoshita M, et al. Prediction of IDH and TERT promoter mutations in low-grade glioma from magnetic resonance images using a convolutional neural network. Sci Rep. 2019;9(1):20311. https:\/\/doi.org\/10.1038\/s41598-019-56767-3","DOI":"10.1038\/s41598-019-56767-3"},{"key":"10.32074\/1591-951X-1812_ref69","doi-asserted-by":"crossref","unstructured":"Corell A, Ferreyra Vega S, Hoefling N, et al. The clinical significance of the T2-FLAIR mismatch sign in grade II and III gliomas: a population-based study. BMC Cancer. 2020;20(1):450. https:\/\/doi.org\/10.1186\/s12885-020-06951-w","DOI":"10.1186\/s12885-020-06951-w"},{"key":"10.32074\/1591-951X-1812_ref70","doi-asserted-by":"crossref","unstructured":"Broen MPG, Smits M, Wijnenga MMJ, et al. The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p\/19q-intact lower-grade glioma: a validation study. Neuro Oncol. 2018;20(10):1393-9. https:\/\/doi.org\/10.1093\/neuonc\/noy048","DOI":"10.1093\/neuonc\/noy048"},{"key":"10.32074\/1591-951X-1812_ref71","doi-asserted-by":"crossref","unstructured":"Cuccarini V, Antelmi L, Pollo B, et al. In vivo 2-hydroxyglutarate-proton magnetic resonance spectroscopy (3 T, PRESS technique) in treatment-naive suspect lower-grade gliomas: feasibility and accuracy in a clinical setting. Neurol Sci. 2020;41(2):347-55. https:\/\/doi.org\/10.1007\/s10072-019-04087-9","DOI":"10.1007\/s10072-019-04087-9"},{"key":"10.32074\/1591-951X-1812_ref72","doi-asserted-by":"crossref","unstructured":"Bhandari A, Sharma C, Ibrahim M, et al. The role of 2-hydroxyglutarate magnetic resonance spectroscopy for the determination of isocitrate dehydrogenase status in lower grade gliomas versus glioblastoma: a systematic review and meta-analysis of diagnostic test accuracy. Neuroradiology. 2021;63(11):1823-30. https:\/\/doi.org\/10.1007\/s00234-021-02702-1","DOI":"10.1007\/s00234-021-02702-1"},{"key":"10.32074\/1591-951X-1812_ref73","doi-asserted-by":"crossref","unstructured":"Cheema PK, Menjak IB, Winterton-Perks Z, et al. Impact of Reflex EGFR\/ ALK Testing on Time to Treatment of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. J Oncol Pract. 2017;13(2):e130-e8. https:\/\/doi.org\/10.1200\/JOP.2016.014019","DOI":"10.1200\/JOP.2016.014019"},{"key":"10.32074\/1591-951X-1812_ref74","doi-asserted-by":"crossref","unstructured":"Gosney JR, Paz-Ares L, Janne P, et al. Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation. ESMO Open. 2023;8(4):101587. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101587","DOI":"10.1016\/j.esmoop.2023.101587"},{"key":"10.32074\/1591-951X-1812_ref75","doi-asserted-by":"crossref","unstructured":"Anand K, Phung TL, Bernicker EH, et al. Clinical Utility of Reflex Ordered Testing for Molecular Biomarkers in Lung Adenocarcinoma. Clinical Lung Cancer. 2020;21(5):437-42. https:\/\/doi.org\/10.1016\/j.cllc.2020.05.007","DOI":"10.1016\/j.cllc.2020.05.007"},{"key":"10.32074\/1591-951X-1812_ref76","doi-asserted-by":"crossref","unstructured":"Pelizzari G, Caggiari L, Battiston M, et al. EP11.01-004 An Effective Two-step Reflex Test for 10 Biomarkers Analysis in Non-small Cell Lung Cancer. JJ Thorac Oncol. 2022;17(9):S510-S1. https:\/\/doi.org\/10.1016\/j.jtho.2022.07.901","DOI":"10.1016\/j.jtho.2022.07.901"},{"key":"10.32074\/1591-951X-1812_ref77","doi-asserted-by":"crossref","unstructured":"Braxton D, Huang Y, Darabi S, et al. Pathology molecular reflex testing improves turn-around-time and overall molecular testing rates in NSCLC. J Clin Oncol. 2021;39:e13507-e. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.e13507","DOI":"10.1200\/JCO.2021.39.15_suppl.e13507"},{"key":"10.32074\/1591-951X-1812_ref78","doi-asserted-by":"crossref","unstructured":"Ceccarelli M, Barthel FP, Malta TM, et al. Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell. 2016;164(3):550-63. https:\/\/doi.org\/10.1016\/j.cell.2015.12.028","DOI":"10.1016\/j.cell.2015.12.028"},{"key":"10.32074\/1591-951X-1812_ref79","doi-asserted-by":"crossref","unstructured":"Johannessen LE, Brandal P, Myklebust TA, et al. MGMT Gene Promoter Methylation Status - Assessment of Two Pyrosequencing Kits and Three Methylation-specific PCR Methods for their Predictive Capacity in Glioblastomas. Cancer Genomics Proteomics. 2018;15(6):437-46. https:\/\/doi.org\/10.21873\/cgp.20102","DOI":"10.21873\/cgp.20102"},{"key":"10.32074\/1591-951X-1812_ref80","doi-asserted-by":"crossref","unstructured":"Tesileanu CMS, van den Bent MJ, Sanson M, et al. Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p\/19q deleted anaplastic glioma. Neuro Oncol. 2021;23(9):1547-59. https:\/\/doi.org\/10.1093\/neuonc\/noab088","DOI":"10.1093\/neuonc\/noab088"},{"key":"10.32074\/1591-951X-1812_ref81","doi-asserted-by":"crossref","unstructured":"Capper D, Stichel D, Sahm F, et al. Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience. Acta Neuropathol. 2018;136(2):181-210. https:\/\/doi.org\/10.1007\/s00401-018-1879-y","DOI":"10.1007\/s00401-018-1879-y"},{"key":"10.32074\/1591-951X-1812_ref82","doi-asserted-by":"crossref","unstructured":"Olar A, Sulman EP. Molecular Markers in Low-Grade Glioma-Toward Tumor Reclassification. Semin Radiat Oncol. 2015;25(3):155-63. https:\/\/doi.org\/10.1016\/j.semradonc.2015.02.006","DOI":"10.1016\/j.semradonc.2015.02.006"},{"key":"10.32074\/1591-951X-1812_ref83","doi-asserted-by":"crossref","unstructured":"Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997-1003. https:\/\/doi.org\/10.1056\/NEJMoa043331","DOI":"10.1056\/NEJMoa043331"},{"key":"10.32074\/1591-951X-1812_ref84","doi-asserted-by":"crossref","unstructured":"Wick W, Weller M, van den Bent M, et al. MGMT testing--the challenges for biomarker-based glioma treatment. Nat Rev Neurol. 2014;10(7):372-85. https:\/\/doi.org\/10.1038\/nrneurol.2014.100","DOI":"10.1038\/nrneurol.2014.100"}],"container-title":["Pathologica"],"original-title":[],"link":[{"URL":"https:\/\/www.pathologica.it\/article\/view\/1812","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T08:16:36Z","timestamp":1779264996000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.pathologica.it\/article\/view\/1812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":84,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,4]]}},"URL":"https:\/\/doi.org\/10.32074\/1591-951x-1812","relation":{},"ISSN":["1591-951X"],"issn-type":[{"value":"1591-951X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"article-number":"5"}}